Cohort (n=323)
Yes
Answers are grounded in this paper and cite their sources.
Introduction Lifestyle change is a class one therapeutic indication for persons with overweight, obesity, metabolic syndrome and cardiovascular risk factors including type II diabetes, hypertension and dyslipidaemia. There is synergism in reducing multiple cardiovacular risk factors simultaneously. Currently there is a need for a formalised prescribed digital therapeutic to enact lifestyle change optimally. We have developed a real-time telemedicine lifestyle change digital therapeutic for persons with these conditions with substantive positive impact on weight, Body Mass Index (BMI), blood pressure (BP), and metabolic syndrome parameters. Purpose To evaluate a digital lifestyle change therapeutic in subjects with metabolic syndrome parameters in primary care, corporate and pharmacy settings. Methods Cohorts of patients were enrolled through primary care physician referrals and in corporate or pharmacy settings; in a GDPR compliant format between 2015–2020 (n=323). The programme offers patient education, guideline dietary recommendations and lifestyle advice specific to the patients requirements via smartphone, tablet or computer. Nudge psychology educational videos, compliment exercise monitored by a smart device and weight loss recorded by a wireless scales. Point of care bloods were tested pre and post-enrollment. Asynchronous dietary advice from a dietician, peer to peer support and an artificial intelligence chat-bot are available at all times via a smartphone application. Statistics used was student two-tailed t-test comparing pretest parameters to those post lifestyle intervention. Results Cohort results are delineated below. As the programme underwent refinement more parameters were added. Nevertheless similar trends are seen in each cohort with statistically meaningful reductions in weight, BMI, systolic and diastolic blood pressure, HbA1c and lipids obtained. Reductions in HbA1c and systolic blood pressure approach or equate with those obtained using drug monotherapy. Moreover the patients Quality of Life is improved. Conclusion A real-time internet-based prescribed lifestyle digital therapeutic results in clinically meaningful reductions in weight, BMI, blood pressure, HbA1c and lipids. Results in various cohorts are similar, indicating a reproducible effect of this cost effective scalable digital therapeutic across a spectrum of metabolic risk factors in a variety of settings. Funding Acknowledgement Type of funding sources: Private company. Main funding source(s): RedicareDiabetes Ireland Table 1
No takes yet. Share an insight, caveat, or question.
Colwell et al. (2021) conducted a cohort in Metabolic syndrome (n=323). Digital lifestyle change therapeutic vs. Pre-intervention baseline was evaluated on Changes in weight, BMI, blood pressure, HbA1c, and lipids. A prescribed digital lifestyle change therapeutic resulted in meaningful reductions in weight, BMI, blood pressure, HbA1c, and lipids compared to pre-intervention baselines.
Synapse has enriched 10 related papers. Consider them for comparative context: